mAbs
Open Access
Journal formatting to fit the target journal guidelines
Experts ensure all elements of your paper match journal formatting guidelines to improve publication success rate!
Aims and Scope
mAbs is a peer-reviewed multi-disciplinary scientific journal established in 2009, published by Taylor & Francis and dedicated to the art and science of antibody research and development. Its editor-in-chief is Janice M. Reichert and it is affiliated with The Antibody Society. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics. It is indexed in MEDLINE, PubMed, the Science Citation Index Expanded, Biological Abstracts, BIOSIS Previews, and Scopus. Less
Key Metrics
View Chart Journal Specifications
- PublisherTAYLOR & FRANCIS INC
- LanguageEnglish
- FrequencyBi-monthly
- Article Processing ChargesGBP 2915
- Publication Time8
- Editorial Review ProcessAnonymous peer review
- LanguageEnglish
- FrequencyBi-monthly
- Publication Start Year2009
- Publisher URL
- Website URL
- Plagiarism
- Publication Time8
- Waiver Policy
- Editorial Team
- Review ProcessAnonymous peer review
- Review Url
- Author instructions
- Copyright Details
- Deposit PolicySherpa/Romeo
- License typeCC BY, CC BY-NC
- OA statement
Ready to spotlight your research findings?
Impress peers and journals alike with a concise, visual summary of your work.
Meets Top Publisher Standards: Essential for leading journals like Elsevier.Enhances Engagement: Research papers with graphical abstracts receive 3X more downloads and 8X more shares.Tailored Just for You: We’ll create a custom graphical abstract based on your manuscript—no sketches needed.
3000+ graphical abstracts produced with 4.8/5 customer rating | Months | % Papers published |
|---|---|
| 0-3 | 33% |
| 4-6 | 50% |
| 7-9 | 13% |
| >9 | 5% |
Topics Covered
Year-wise Publication
- 5Y
- 10Y
FAQs
Since when has mAbs been publishing? 
The mAbs has been publishing since 2009 till date.
How frequently is the mAbs published?
mAbs is published Bi-monthly.
Who is the publisher of mAbs?
The publisher of mAbs is TAYLOR & FRANCIS INC.
Where can I find a journal's aims and scope of mAbs?
For the mAbs's Aims and Scope, please refer to the section above on the page.
How can I view the journal metrics of mAbs on editage?
For the mAbs metrics, please refer to the section above on the page.
What is the eISSN and pISSN number of mAbs?
The eISSN number is 1942-0870 and pISSN number is 1942-0862 for mAbs.
What is the focus of this journal?
The journal covers a wide range of topics inlcuding Biosimilar, Monoclonal antibody, Immunoglobulin G, Heavy chain, Bispecific antibody, Dual targeting, Lymph node, Mass spectrometry, Central nervous system, Crystal structure, Antitumor response, Biopharmaceutical, High affinity binding, Phage display, Inflammatory arthritis, Protective antibody, Target antigen, Sequence analysis, Antigen binding, Tumor microenvironment.
Why is it important to find the right journal for my research?
Choosing the right journal ensures that your research reaches the most relevant audience, thereby maximizing its scholarly impact and contribution to the field.
Can the choice of journal affect my academic career?
Absolutely. Publishing in reputable journals can enhance your academic profile, making you more competitive for grants, tenure, and other professional opportunities.
Is it advisable to target high-impact journals only?
While high-impact journals offer greater visibility, they are often highly competitive. It's essential to balance the journal's impact factor with the likelihood of your work being accepted.